Skip to main content

Health-related quality of life in undergraduate women using any contraceptive



The aim of this research was to assess university students’ health-related quality of life whether they use some contraceptive method or not.


This research is a cross-sectional study. Female participants who studied a degree in health at the University of Seville (Spain) were recruited. Respondents completed a demographic questionnaire and health-related quality of life was measured with validated instrument SEC-QoL (Sociedad Española de Contracepción- Quality of Life) in Spanish that measured five dimensions: sexual, social, breast, menstrual and psychosocial.


A total of 992 women aged 21.37 (3.6) years old participated in this study. Women who used a contraceptive method reached higher scores at the SEC-QoL questionnaire 47.09 (17.04) and 46.91 (18.73) than those that didn’t. Likewise, women who chose a hormonal method showed a better overall health-related quality of life, compared to those who used a non-hormonal method. Participants who used hormonal contraceptives obtained higher scores in all health-related quality of life domains (social, menstrual, breast and sexual), except psychological domain when compared to those who used a non hormonal method or none. Furthermore, a moderated mediation model showed that the effect of the current contraceptive method on health-related quality of life was partially explained by the moderated mediation of the time using this method, the reason for using it and the existence of a partner.


The usage of hormonal contraceptives increases health-related quality of life in young women. Several variables regarding the experience with contraceptive methods should be considered in order to examine the effect on health-related quality of life in undergraduate women.

Plain English summary

Contraceptives present benefits for young women beyond avoiding a pregnancy. This research was designed to assess the impact of contraception on health-related quality of life. A cross-sectional study was carried out with a sample of 992 female university students from the University of Seville using SEC-QoL (Sociedad Española de Contracepción- Quality of Life) scale validated by the Spanish Society of Contraception. The use of any contraceptive method improves women’s quality of life measured. Women who used a hormonal contraceptive had higher health-related quality of life scores. The use of hormonal methods improves all domains in young women, except for the psychological domain at SEC-QoL scale. Several variables about the use of contraceptive methods should be considered in order to examine the effect on health-related quality of life.


Contraceptive methods present benefits besides contraception [1]. Nevertheless, many women and health professionals are not aware of them [2]. Contraceptives were initially developed to plan pregnancies; however; many studies have demonstrated non-contraceptive benefits [3]. Among these benefits, it was found that hormonal contraceptives reduced menstrual blood loss, dysmenorrhoea and premenstrual syndrome (PMS) [4]. Moreover, they reduce the later incidence of endometrial and ovarian cancer and appear to help to protect future fertility by reducing the risk of acute pelvic floor inflammatory disease, endometriosis and uterine fibroids [5].

Premenstrual symptoms are common in reproductive-aged women. PMS refers to the cyclic occurrence of a set of disturbing physical, emotional or behavioral alterations that are of sufficient severity to interfere with interpersonal relations and routine life, affecting quality of life [6]. Epidemiological studies carried out in Spain showed that 73.7% of menstruating women are affected by some premenstrual symptoms during the menstrual cycle [7], including headaches and premenstrual mood changes, such as anxiety, irritability or fatigue, that are present during spontaneous menstrual cycles and during the use of oral contraceptives [8] with or without a hormone free interval. The impact of premenstrual symptoms on the daily life of women depends on the severity of such symptoms [9]. Many symptoms of PMS are associated with poor health-related quality of life [10, 11] affecting mental, emotional and physical domains [11, 12]. Some studies confirm beneficial effects of hormones on mood [13] and physical symptoms of PMS, while others failed to show effectiveness of hormones [14, 15].

Previous research has demonstrated that using hormonal contraceptives can theoretically reduce PMS symptoms in all forms of hormonal contraception [16]. These effects demonstrate that contraceptives should be taken into consideration regarding quality of life, so this has become a great issue in all health systems [17, 18].

There are studies where women’s health in relation with their quality of life has been measured using standard questionnaires such as EuroQol-5D (EQ-5D) [19], SF-36 [20, 21], World Health Organization’s Quality of Life (WHOQOL) [22, 23], Psychological General Well-Being Index (PGWBI) [18, 24] or Quality of life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) [25]. The Spanish Contraception Society developed a survey in Spanish to specifically measure women’s health-related quality of life when using contraceptive methods [26,27,28]. This questionnaire, called SEC-QoL (Sociedad Española de Contracepción- Quality of Life) is the only one designed for fertile women providing information on five dimensions.

This study tries to assess associations between contraceptive choice and women’s health-related quality of life in a sample of university students.


Study design and participants

We conducted a cross-sectional study among students at the University of Seville from June to October 2015. Participants answered a self-administered questionnaire based on SEC-QoL, sociodemographic variables and questions about the use of contraceptives and sexual habits: a) current contraceptive method being used; b) contraceptive methods used throughout life; c) partner; d) time with a relationship; e) number of sexual partners in the last year; f) frequency of sexual relations; g) age at first sexual relation; h) motivation to use current contraceptive method.

Women were eligible to participate in this study whether they were: a) older than 18 years; b) having menstrual cycle monthly (except women who do free-interval with hormonal contraceptives). Women who reached menopause were excluded.


Quality of life was assessed with the SEC-QoL questionnaire (see Appendix). The questionnaire was created to assess the impact of contraceptive methods on the health-related quality of life of women. They assumed that the effects associated with the menstrual cycle had an influence on health-related quality of life, particularly in women who used hormonal methods [26].

This is a self-administered questionnaire consisting of 19 items and five domains: social (consisting of 5 items), menstrual symptoms (4 items), breast symptoms (3 items), psychological (4 items) and sexual (3 items). Each item is scored from 1 to 5 likert response choices (from “always” to “never” or from “totally agree” to “totally disagree” depending on the statement). The total score range is 0–100.

This questionnaire showed a good internal consistency with an overall Cronbach’s alpha of 0.88 and a value higher than 0.70 in all domains, except for the sexual domain (0.55). The overall intra-class correlation coefficient was 0.82, which was higher than 0.70 in all domains, thus indicating the good test-retest reliability of the questionnaire (25).

Standardization is obtained as follows: (current score- minimum score)/ (maximum score-minimum score) *100.

Ethics, consent and permissions

The study was approved by the Ethical committee at the University of Seville and written informed consent was obtained from each participant. The study protocol conformed to the ethical guidelines of the 1975 Helsinki declaration.

Statistical methods

A descriptive analysis of the sociodemographic characteristics was performed in IBM Corp. Released 2013. IBM Statistical Package for the Social Sciences (SPSS) for Windows, Version 21.0. Armonk, NY: IBM Corp. We compared the characteristics of patients who used any contraceptive method to patients without recent contraceptive use and users of a hormonal method and others. Data were expressed as absolute frequencies, average and percentages. The differences in SEC-QoL scores between hormone users and non-users were calculated by analysis of variance and by chi-square test. A p value of less than 0.05 was considered as indicating significance for these analyses. 95% confidence intervals were calculated assuming a Poisson distribution.

Finally, some mediation and moderation analyses were performed to further explore the type of relationships among the study variables. These analyses were carried out following the recommendations described by Preacher et al. [29], based on regression analyses. The effects described in this model represent causal assumptions, because there is no causation verification without variable manipulation. Thus, only associations among variables may be concluded. Standardized coefficients were calculated to estimate the effect of one variable (assumed to be the independent variable) on another variable (assumed to be the criterion variable). Process v3.0 macro for SPSS was used [30], by specifically applying the model number 68, developed by Hayes (2017). A total of 1000 bootstrap samples were estimated for bias-corrected bootstrap confidence intervals for specific indirect effects [31]. This model tested the mechanisms which may underline the relationship between the current contraceptive method being used and health-related quality of life. Time using the contraceptive method is expected to partially mediate this effect on health-related quality of life. In turn, the reason for using the contraceptive method and having a partner or not are proposed to moderate such partial mediation. These analyses were sequentially performed before being integrated in the overall moderated mediation model.


This study was carried out within a cohort of university students. Population included 1007 women aged between 17 and 54 years old who were enrolled in any of the degrees at the Faculty of Nursing, Physiotherapy and Podiatry from the University of Seville (Spain). A total of 992 (98.5%) women aged between 18 and 50 years old answered the questionnaire, two of which did not meet inclusion criteria because of menopause. Sociodemographic characteristics of participants are shown in Table 1.

Table 1 Sociodemographic characteristics of study participants

The age of participants was 21.37 years old (3.60). All women included were studying a degree in health science at university.

Sexual habits of participants

Participants who had a partner were 67.60% (665) and were engaged in a relationship that lasted an average of 36.27 (32.02) months. The initiation of sexual intercourse among women who answered was at 16.71 (1.78) years old. Most common frequency of sex was once-twice a week 40.62% (403), more than twice a week 21.37% (212); once-twice a month 19.10% (189) and once-twice a year 4.58% (48). Female students that had not had sex before were 9.90% (98).

Contraceptive habits of participants

Contraceptive use in women who participated in this study is 90.6%. Students who had used a condom at least once in their lives were 84.57% (839); coitus interruptus by 24.39% (242), hormonal contraceptive pills by 42.54% (422), hormonal vaginal ring by 10.18% (101); contraceptive patches by 1% (10) and subdermal implant by 0.10% (1).

The current most widely used contraceptive method is the condom: 47.07% (467), followed by contraceptive pills: 23.28% (231), and 12.2% (115) do not use any method. However, only a 9.90% (98) referred that they had not had sex before, so 2.52% had sex without using any contraceptive method. Timing using the current method is 24 months (p25 (12)-p75 (48)).

Motivation to choose a method is based on security (55.14% (547)), prevention of sexual transmission infection (STI) (14.61% (145)), ease of use (6.35% (63)), price (1.91% (19)), availability (1.71% (17)). Women who chose a method to prevent STI used a condom more often (p < 0.001)

Quality of life scale

Participants´ mean score (SD) was 54.57 (13.26), (95% CI 53.74 to 55.39) at global SEC-QoL score. If we analyze women who use a contraceptive method in comparison to women who do not, mean scores are 47.09 (17.04) and 46.91 (18.73) respectively. If we detail each score depending on the method we find that hormonal methods show higher scores as it is shown in Table 2. Women using hormonal contraceptive methods reported greater SEC-QoL scores than women using non hormonal ones (p < 0.001).

Table 2 Health-related quality of life by method of contraception

When observing every single sub-scale, statistically significant differences were seen between women using hormonal contraceptives and women not using them, as Table 3 shows, except for the psychological dimension. We assume that the most affected domain between young women during the menstrual cycle is the breast symptoms one and the least affected one is the social domain. On the other hand, domains with more differences between hormonal method users and non-users are menstrual symptoms and the sexual domain observing higher scores in hormonal contraceptive users.

Table 3 Scores in health-related quality of life domains, by the use of hormonal methods or not

Health-related quality of life by age did not show any differences among groups under and over 30 years old (46.85 (17.12) vs 47.88 (27.72), p = 0.781, 95% CI (− 8.24, 6.19). Time using a contraceptive method is not related to higher SEC-QoL scale scores (p > 0.05). In bivariate analysis women who have been using hormonal contraceptives longer did not show better scores (p > 0.05). However, significant differences were found between women using hormonal contraceptives who had sex more frequently than women who did not (p < 0.001).

Moderated mediation model

First, results showed that there were differences in SEC-QoL by the contraceptive method used (β = 0.12, p = 0.004, 95% CI [0.04, 0.20]), so that higher scores in SEC-QoL were found in participants who used hormonal methods (M = 51.32, SD = 17.86), while lower scores were observed in those who used non-hormonal methods (M = 46.08, SD = 16.57), F(2, 861) = 8.69, p < 0.001, η2p = 0.02. Second, these differences on SEC-QoL were partly related to the time using that method. Moreover, the reason for using the contraceptive method and having a partner were proposed as moderators in that partial mediation. Results showed, on the one hand, some differences in the time using the current contraceptive method according to the specific method (β = − 0.11, p = 0.010, 95% CI [− 0.20, − 0.03]. Consequently, participants who used non-hormonal methods reported more months using them (M = 35.42, SD = 29.74) than those who used hormonal methods (M = 28.15, SD = 25.04), which is expectable on the basis of participants’ sexual life course. Moreover, the relationship between the current contraceptive method and the time in months using that method was found to be moderated by the reason for using it and having a partner or not (β = − 0.10, p = 0.021, 95% CI [− 0.19, − 0.02]), F(7, 545) = 3.16, p = 0.003, R2 = 0.04. Thus, among participants who used non-hormonal contraceptive methods because of its security, those who had a partner reported more months using it (M = 36.32, SD =30.20) than those without a partner (M = 26.86, SD = 22.82). Moreover, among participants who used non-hormonal contraceptive methods because of its availability, those who had a partner reported more months using it (M = 27.11, SD = 38.77) than those without a partner (M = 18.00, SD = 8.49). On the other hand, results indicated that the motive to use the current contraceptive method also moderated the relationship between the time using it and the scores in SEC-QoL (β = 0.11, p = 0.004, 95% CI [0.04, 0.19]), F(3, 567) = 4.73, p = 0.002, R2 = 0.02. Among participants who had used the current contraceptive methods for more than 24 months, the motives of availability (M = 72.00, SD = 19.97) and price (M = 63.17, SD = 17.45) were associated with higher health-related quality of life compared to those participants with less than 24 months using that method (M = 53.22, SD = 9.77, and M = 56.46, SD = 14.19, respectively). Moreover, greater health-related quality of life was also found in undergraduate women that used the current contraceptive method for more than 24 months in order to prevent an STI (M = 58.76, SD = 12.83), compared to those who shared this same motive but had used the method for less time (M = 55.80, SD = 12.99). However, no significant association was observed between the time using the contraceptive method and health-related quality of life scores (β = 0.03, p = 0.436, 95% CI [− 0.05, 0.12]. Figure 1 presents the integration of the previous results into a single moderated mediation model. Thus, this model showed that the relationship between the current contraceptive method and the scores in overall SEC-QoL was partially associated with the moderated mediation of time in months using this method, the motive to use this method and having a partner or not, F(4, 548) = 5.81, p < 0.001, R2 = 0.04.

Fig. 1
figure 1

Moderated mediation model of health-related quality of life according to current contraceptive method, time using this method, motive to use it, and having a partner


The questionnaire used in this study is specific for women using contraceptive methods to address its effect on health-related quality of life. We measured five health-related quality of life dimensions (social, menstrual symptoms, breast symptoms, psychological and sexual) that allowed us to find differences related to the use of contraceptives. There have been few studies assessing the impact of contraceptive use on women’s quality of life with such a specific questionnaire as SEC-QoL [26,27,28].

This study found that women who use any contraceptive method have higher scores of SEC-QoL than those who use no contraceptive. When comparing different methods of contraception, women who used hormonal methods had higher scores. Actually, women who use any form of contraception may have an improved health-related quality of life and different contraceptive methods have varying degrees of impact on women’s. However, it is difficult to determine the exact impact of contraception on health-related quality of life [32] so this is a multifactorial construct involving social and cultural factors [33].

We asked about the motivation for using contraceptives. Some may use them to prevent a pregnancy and others for non-contraceptive benefits. The main reason is to avoid unplanned pregnancies. In other studies, with young women, the main reason for choosing a method is to plan a pregnancy [34].

Women obtained more benefits other than contraceptive effects. Menstrual symptoms’ dimension of SEC-QoL was shown to be less severe in women who chose hormonal contraceptive methods. In our study, we observed an improvement in these domains of SEC-QoL in those women who chose hormonal contraceptive method: breast tenderness, social, menstrual and sexual symptoms. These results are consistent with previous studies [23, 35]. Likewise, the psychological domain was higher in the group that took oral contraceptives, but not in a statistically significant manner. This is similar to what happened in other studies where the scores of the groups that used hormonal methods were significantly improved by taking oral contraceptives [36]. According to previous studies, premenstrual breast tenderness had a great impact on the life of women who experienced it [37, 38]. In our study, women who use a hormonal contraceptive feel that breast tenderness less. When these adverse events are reduced, this contributes to improving overall health-related quality of life. However, whether the combined oral contraceptive pill reduces breast pain is not clear [37].

There is a lack of knowledge about how contraceptives affect sexual function. Zethraeus et al. showed no negative impact of oral contraceptives on overall sexual function [39]. In this line, our study showed that women who used contraceptive methods had fewer score in the dimensions of menstrual and better sexual health-related quality of life. Similar results were obtained by Caruso et al. [38]. We also observed that women using oral contraceptives had sex more frequently. On the other hand, other studies showed that combined oral contraceptives did not improve sexual life or health-related quality of life [22]. Besides, many factors may contribute to having effects on female sexuality, such as psychosocial and cultural influences [38].

This sample is formed by women in their twenties, so we do not have users of definitive methods or intrauterine dispositive, more common in older women. Most women in this study reported using hormonal methods or a condom as in others studies carried out in Spain [34, 40]. We cannot establish a relationship between those methods and health-related quality of life as it was showed in other pieces of research [26, 41] since these methods are mostly used among elder women. As a contribution of the present research, a moderated mediation model has been developed to examine the interactive effects of some variables regarding the use of contraceptive methods on the overall scores in health-related quality of life. This model showed that the current contraceptive method had a relationship with health-related quality of life both directly and through its relationships with the time using it, the motive to use it and having a partner or not. Thus, several variables should be considered in order to study the health-related quality of life of undergraduate women on the basis of their experience with contraceptive methods [42].

The amount of time using a method is not directly related to higher scores, so we could presume that positive effects are felt sooner. Students who have been using contraceptives longer did not show higher scores on health-related quality of life. Zocal’s study showed that after 6 months SEC-QoL global and dimension scores had greater increases from baseline in women who chose to switch to combined oral contraception based on natural estrogen [27]. A revision by Lopez et al. found better scores after only 3 months [1].

As a limitation of this study, we state that we did not measure the longitudinal effect of contraception on premenstrual syndrome from a baseline. We asked women about their perception of health-related quality of life at one specific point and in retrospect by applying a questionnaire. Other limitation that should be acknowledged is the need to assess other relevant variables, such as beliefs about premenstrual symptoms [43], and a further examination of all the premenstrual symptoms listed in Diagnostic and Statistical Manual of Mental Disorders – V (DSM-V). Due to possible bias toward false positive reports in retrospective self-report measures of premenstrual changes, prospective daily monitoring of all symptoms for at least two consecutive menstrual cycles may be recommended [44]. Moreover, the type and amount of hormones that women took should be controlled, and this improvement may be recommended as a future research line. Furthermore, because a cross-sectional design was followed, only associations among variables can be concluded. The moderated-mediation model based on regression analyses only represents causal assumptions. A longitudinal design is recommended to examine relationships between antecedents and consequents and an experimental design is required to test causal effects.


The achieved results suggest higher scores of SEC-QoL in women using hormonal contraceptive methods. Overall, women reported better menstrual health-related quality of life, lower breast tenderness and a better sexual life.



Diagnostic and Statistical Manual of Mental Disorders – V




Psychological General Well-Being Index


Premenstrual syndrome


Quality of life Enjoyment and Satisfaction Questionnaire


Sociedad Española de Contracepción- Quality of Life


Statistical Package for the Social Sciences


Sexual transmission infection


  1. Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database of Systematic Reviews 2012, Issue 2. Art. No.: CD006586. doi:

  2. Dehlendorf C, Levy K, Ruskin R, Steinauer J. Health care providers’ knowledge about contraceptive evidence: a barrier to quality family planning care? Contraception. 2010;81(4):292–8.

    Article  PubMed  Google Scholar 

  3. Bahamondes L, Bahamondes MV, Shulman LP. Non-contraceptive benefits of hormonal and intrauterine reversible contraceptive methods. HumReprod Update. 2015;21(5):640–51. Epub 2015 Jun 1.

    Article  CAS  Google Scholar 

  4. Hillard PA. Menstrual suppression: current perspectives. Int J of Womens Health. 2014;6:631–7.

    Article  Google Scholar 

  5. Fraser IS, Kovacs GT. The efficacy of non-contraceptive uses for hormonal contraceptives. Med J Aust. 2003;178(12):621–3.

    PubMed  Google Scholar 

  6. Hatcher RA, Trussell J, Nelson AL, Cates JW, Stewart FH, Kowal D. Contraceptive technology. 19th ed. New York: Ardent Media, Inc; 2007. p. 210–3.

    Google Scholar 

  7. Lete I, Dueñas JL, Serrano I, Doval JL, Martínez-Salmeán J, Coll C, et al. Attitudes of Spanish women toward premenstrual symptoms, premenstrual syndrome and premenstrual dysphoric disorder: results of a nationwide survey. Eur J Obst and Gynecology and Reproductive Biology. 2011;159(1):115–8.

    Article  Google Scholar 

  8. Sulak PJ, Scow RD, Preece C, Riggs MW, Kuehl TJ. Hormone withdrawal symptoms in oral contraceptive users. ObstetGynecol. 2000;95(2):261–6.

    CAS  Google Scholar 

  9. Mishell DR. Premenstrual disorders: epidemiology and disease burden. Am J Managed Care. 2005;11:S473.

    Google Scholar 

  10. Henderson C. ACOG issues guide-lines on diagnosis and treatment of PMS. Women's Health Weekly. 2000;5(6):20–2.

    Google Scholar 

  11. Yang M, Wallenstein G, Hagan M, Guo A, Chang J, Kornstein S. Burden of premenstrual dysphoric disorder on health-related quality of life. Int J Womens Health. 2008;17:113–21.

    Article  Google Scholar 

  12. Al-Batanony MA, AL-Nohair SF. Prevalence of premenstrual syndrome and its impact on quality of life among UniversityMedical students, Al Qassim University, KSA. Public HealthResearch. Scientific & Academic Publishing 2014;4(1):1–1):6.

  13. Oinonen KA, Mazmanian DT. To what extent do oral contraceptives influence mood and affect? J Affect Disord. 2002;70(3):229–40.

    Article  CAS  PubMed  Google Scholar 

  14. Bakhshani NM, Hosseinbor M. ShahrakiZ,Sakhavar N. premenstrual syndrome symptomatology among married women of fertile age based on methods of contraception (hormonal versus non-hormonal methods of contraception). Glob J Health Sci. 2014;6(2):105–11

    Google Scholar 

  15. Joffe H, Cohen LS, Harlow BL. Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration. Am J ObstetGynecol. 2003;189:1523.

    Article  CAS  Google Scholar 

  16. Sadler C, Smith H, Hammond J, et al. Lifestyle factors, hormonal contraceptives and premenstrual symptoms: The UK Southampton Women’s Survey. JJ Womens Health (2002). 2010;19(3):391–6.

    Article  Google Scholar 

  17. Borenstein J, Yu HT, Wade S, Chiou CF, Rapkin A. Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life. J Reprod Med. 2003;48(2):79–85.

    CAS  PubMed  Google Scholar 

  18. Apter D, Borsos A, Baumgärtner W, Melis GB, Vexiau-Robert D, Colligs-Hakert A, Palmer M, Kelly S. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur J ContraceptReprod Health Care. 2003;8(1):37–51.

    Article  CAS  Google Scholar 

  19. Bastianelli C, Farris M. BenagianoG.Use of the levonorgestrel-releasing intrauterine system, quality of life and sexuality. Experience in an Italian family planning center. Contraception. 2011;84(4):402–8.

    Article  PubMed  Google Scholar 

  20. Unsal A, Ayranci U, Tozun M, Arslan G, Calik E. Prevalence of dysmenorrhea and its effect on quality of life among a group of female university students. Ups J Med Sci. 2010;115(2):138–45.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Caruso S, Iraci M, Cianci S, Fava V, Casella E, Cianci A. Comparative,open-label prospective study on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain on 2 mg dienogest/30 μg ethinyl estradiol continuous or 21/7 regimen oral contraceptive. J Endocrinol Investig. 2016;39(8):923–31.

    Article  CAS  Google Scholar 

  22. Li RH, Lo SS, Teh DK, Tong NC, Tsui MH, Cheung KB, Chung TK. Impact of common contraceptive methods on quality of life and sexual function in Hong Kong Chinese women. Contraception. 2004;70(6):474–82.

    Article  PubMed  Google Scholar 

  23. Farrokh-Eslamlou H, Oshnouei S, Heshmatian B, Akbari E. Premenstrual syndrome and quality of life in Iranian medical students. SexReprodHealthc. 2015;6(1):23–7. Epub 2014 Jun 30.

    Article  Google Scholar 

  24. Winkler UH, et al. Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 μgethinylestradiol. Contraception. 2004;69(6):469–76.

    Article  CAS  PubMed  Google Scholar 

  25. Egarter C, Topcuoglu MA, Imhof M, Huber J. Low dose oral contraceptives and quality of life. Contraception. 1999;59(5):287–91.

    Article  CAS  PubMed  Google Scholar 

  26. Pérez-Campos E, Dueñas JL, de la Viuda E, Gómez MÁ, Lertxundi R, Sánchez-Borrego R, et al. Development and validation of the SEC-QoL quality of life questionnaire in women using contraceptive methods. Value Health. 2011;14:892–9.

    Article  PubMed  Google Scholar 

  27. Lete I, de la Viuda E, Pérez-Campos E, Martínez MÁ, Sanchez-de la Rosa R, Novalbos J, Sánchez-Borrego R. Effect on quality of life of switching to combined oral contraception based on natural estrogen: an observational, multicentre, prospective phase IV study (ZOCAL study). Eur J ContraceptReprod Health Care. 2016;21(4):276–84. Epub 2016 May 25.

    Article  CAS  Google Scholar 

  28. Cristobal I, Lete LI, Viuda Ede L, Perulero N, Arbat A, Canals I. One year quality of life measured with SEC-QoL in levonorgestrel 52 mg IUS users. Contraception. 2016;93(4):367–71. Epub 2016 Jan 4.

    Article  CAS  PubMed  Google Scholar 

  29. Preacher KJ, Rucker DD, Hayes AF. Addressing moderated mediation hypotheses: theory, methods, and prescriptions. Multivar Behav Res. 2007;42:185–227.

    Article  Google Scholar 

  30. Hayes AF. Introduction to mediation, moderation, and conditional process analysis: a regression-based approach. New York: Guilford Publications; 2017.

  31. Hayes AF. An index and test of linear moderated mediation. MultivariateBehavioralResearch. 2015;50:1–22.

    Article  Google Scholar 

  32. Williams SL, Parisi SM, Hess R, Schwarz EB. Associations between recent contraceptive use and quality of life among women. Contraception. 2012;85(3):282–7. Epub 2011 Sep 19.

    Article  PubMed  Google Scholar 

  33. Robert SA, Cherepanov D, Palta M, Dunham NC, Feeny D, Fryback DG. Socioeconomic status and age variations in health-related quality of life: results from the National Health Measurement Study. J Gerontol B PsycholSciSocSci. 2009;64:378–89.

    Article  Google Scholar 

  34. Johnson S, Pion C, Jennings V. Current methods and attitudes of women towards contraception in Europe and America. Reprod Health. 2013;10:7.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Lustyk MK, Widman L, Paschane A, Ecker E. Stress, quality of life and physical activity in women with varying degrees of premenstrual symptomatology. Women Health. 2004;39:35–44.

    Article  PubMed  Google Scholar 

  36. Matsumoto Y, Yamane S, Ideta K, Kawabata M. Impact of use of combined or MHRQo al contraceptive pill on the quality of life of Japanese women. J ObstetGynaecol Res. 2007;33:529–35.

    Google Scholar 

  37. Goyal A. Breast pain. BMJ ClinEvid. 2011;812 Accessed 15 May 2019.

  38. Caruso S, Malandrino C, Cicero C, Ciancio F, Cariola M, Cianci A. Quality of sexual life of women on oral contraceptive continued-regimen: pilot study. J Sex Med. 2013;10:460–6.

    Article  CAS  PubMed  Google Scholar 

  39. Zetharaeus N, Dreber A, Ranehill E, Blomberg L, Labrie F, Shoultz V, et al. A first-choice combined oral contraceptive influences general well-being in healthy women: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility. 2017;107(5):1238–45.

    Article  Google Scholar 

  40. Carrasco-Garrido P, López de Andrés A, Hernández-Barrera V, et al. Trends in the use of oral contraceptives among adolescents and young women in Spain. Reprod Health. 2016;13:122.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Caruso S, Cianci S, Vitale SG, Fava V, Cutello S, Cianci A. Sexual function and quality of life of women adopting the levonorgestrel-releasing intrauterine system (LNG-IUS 13.5 mg) after abortion for unintended pregnancy. Eur J ContraceptReprod Health Care. 2018;23(1):24–31.

    Article  CAS  Google Scholar 

  42. Lemoine J, Teal SB, Peters M, Guiahi M. Motivating factors for dual-methodcontraceptive use among adolescents and young women: a qualitative investigation. Contraception. 2017;96(5):352–6.

    Article  PubMed  Google Scholar 

  43. Cohen LS, Soares CN, Otto MW, Sweeney BH, Liberman RF, Harlow BL. Prevalence and predictors of premenstrual dysphoric disorder (PMDD) in older premenopausal women. The Harvard Study of Moods and Cycles J Affect Disord. 2002;70(2):125–32.

    Article  PubMed  Google Scholar 

  44. Eisenlohr-Moul TA, Girdler SS, Schmalenberger KM, Dawson DN, Surana P, Johnson JL, Rubinow DR. Toward the reliable diagnosis of DSM-5 premenstrual dysphoric disorder: the Carolina premenstrual assessment scoring system (C-PASS). Am J Psychiatr. 2016;174(1):51–9.

    Article  PubMed  Google Scholar 

Download references


To the Spanish Society of Contraception for authorizing the use of SEC-QoL instrument for this study and to all respondents who participated in this research.

Provenance and peer review

not commissioned; externally peer reviewed.


This research was supported by the authors.

Availability of data and materials

All generated or analyzed data during this study are included in this published article.

Author information

Authors and Affiliations



FLL, NC designed the study. JMS & FLL performed the data analysis and FLL, CVV & ASS wrote the first draft of manuscript. DGB supervised the analysis and the draft. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Diego Gomez-Baya.

Ethics declarations

Ethics approval and consent to participate

The protocol for this project was submitted to the Ethical committee at the University of Seville and it was approved. All procedures performed were in accordance with the ethical standards of the institution and with the 1964 Helsinki declaration and its subsequent amendments or with comparable ethical standards.

Consent for publication

All participants have given consent for publication.

Competing interests

The authors declare that they have no conflict of interest.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



The SEC-QoL Questionnaire

This English version of the questionnaire is a simple translation of the Spanish version to show its contents.

  1. 1.

    I have menstrual pain (pain in the lumbar area and abdomen) a few days before my period starts.

  2. 2.

    I feel a mild discomfort in the kidney area a few days before my period starts.

  3. 3.

    I feel discomfort in the ovary area during my period.

  4. 4.

    My breasts feel harder during my period.

  5. 5.

    I feel that my breasts increase in size on the days before my period starts.

  6. 6.

    My breasts increase in size during my period.

  7. 7.

    I feel more nervous and I have less patience on the days before and during the first few days of my period.

  8. 8.

    My legs feel more tired on the days before and during the first few days of my period.

  9. 9.

    On the days before and during the first few days of my period, I do not feel like doing sport or any activity that is related to sudden movement.

  10. 10.

    On the days before and during the first few days of my period I prefer to be calmer and to do fewer things.

  11. 11.

    When my period coincides with the weekend, I refrain from doing things because of physical discomfort.

  12. 12.

    When I have my period I am more nervous at work.

  13. 13.

    My sexual desire decreases during the days of my period.

  14. 14.

    On the days before and during the first few days of my period, I feel nervous and susceptible (I get upset about anything).

  15. 15.

    I worry that I may have hormonal disorders.

  16. 16.

    When my period comes, my performance at work is somewhat lower because of menstrual pain.

  17. 17.

    I worry that the birth control method I use in my sexual relations may fail.

  18. 18.

    During the first few days of my period, when bleeding is heavier, I refuse sexual intercourse.

  19. 19.

    During my period, I feel that I have less energy (everything requires me more effort).

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Leon-Larios, F., Vazquez-Valeo, C.G., Sanchez-Sanchez, A. et al. Health-related quality of life in undergraduate women using any contraceptive. Health Qual Life Outcomes 17, 90 (2019).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: